What is the best way to prevent transmission of herpes simplex virus type 2 (HSV‑2)?

Best Way to Prevent Spreading HSV-2

The most effective strategy to prevent HSV-2 transmission combines daily suppressive antiviral therapy with consistent condom use and abstinence during symptomatic outbreaks. 1, 2

Primary Prevention Strategy: Daily Suppressive Therapy

Daily suppressive therapy with valacyclovir 500 mg once daily reduces HSV-2 transmission risk by 48% and symptomatic disease transmission by 75% in heterosexual HSV-2-discordant couples. 3, 4 This represents the single most effective pharmacologic intervention for preventing transmission. 5

Recommended Suppressive Regimens

• Valacyclovir 500 mg orally once daily is the preferred regimen based on the landmark transmission study demonstrating significant reduction in both symptomatic and overall HSV-2 acquisition. 3, 2
• Alternative regimens include acyclovir 400 mg orally twice daily or famciclovir 250 mg orally twice daily, though these lack specific transmission reduction data. 2
• Suppressive therapy reduces asymptomatic viral shedding from 10.8% of days to 2.9% of days, which is the primary mechanism for preventing transmission. 3

Critical Limitation in HIV-Coinfected Individuals

Suppressive antiviral therapy does NOT reduce HSV-2 transmission risk in persons coinfected with HIV and HSV-2. 6, 7 A randomized controlled trial of 911 HSV-2/HIV-1-discordant couples found that daily acyclovir 400 mg twice daily actually showed a non-significant trend toward increased HSV-2 transmission (hazard ratio 1.35,95% CI 0.83-2.20). 6 This is a crucial pitfall—do not counsel HIV-positive patients that suppressive therapy will reduce their HSV-2 transmission risk. 7, 1

Essential Behavioral Interventions

Condom Use

• Consistent condom use during all sexual exposures should be strongly encouraged, as it provides additional protection beyond suppressive therapy. 1, 2
• Condoms offer partial protection but do not eliminate transmission risk, as HSV-2 can be shed from areas not covered by condoms. 1

Abstinence During Symptomatic Periods

• Patients must abstain from all sexual activity when lesions or prodromal symptoms are present. 1, 8
• Viral shedding is highest during symptomatic outbreaks, making transmission risk substantially elevated during these periods. 1

Critical Patient Counseling Points

Asymptomatic Viral Shedding

• Transmission frequently occurs during asymptomatic periods when no visible lesions are present. 1, 5 This is the most important concept for patients to understand.
• Asymptomatic shedding accounts for approximately one-third of all viral shedding days and occurs in the majority of HSV-2-infected individuals. 5
• Asymptomatic shedding is most frequent during the first year after infection but continues throughout the lifetime of infection. 5

Partner Notification and Testing

• All sexual partners should be informed of the HSV-2 diagnosis and offered counseling and serologic testing. 1
• Partners with known HSV-2 exposure and high pretest probability should undergo HSV-2 serologic testing to establish their infection status. 1

Algorithmic Approach to Prevention Counseling

For all HSV-2-infected individuals in serodiscordant relationships:

1. Offer daily suppressive therapy (valacyclovir 500 mg once daily) and explain the 48% reduction in transmission risk. 3, 2
2. Emphasize consistent condom use during all sexual encounters, even while on suppressive therapy. 1, 2
3. Mandate abstinence when any prodromal symptoms or visible lesions are present. 1, 8
4. Counsel about asymptomatic shedding and that transmission can occur even without symptoms or while on suppressive therapy. 1, 5

For HIV/HSV-2 coinfected individuals:

1. Do NOT recommend suppressive therapy for transmission prevention, as it is ineffective in this population. 6, 7
2. Focus exclusively on behavioral interventions: consistent condom use and abstinence during symptomatic periods. 1
3. Consider suppressive therapy only for reducing recurrence frequency, not for transmission prevention. 1

Common Pitfalls to Avoid

• Never counsel that suppressive therapy eliminates transmission risk—it reduces but does not eliminate asymptomatic viral shedding or transmission potential. 1, 3
• Do not recommend suppressive therapy for transmission prevention in HIV-positive patients, as randomized controlled trial data show no benefit. 6
• Avoid giving false reassurance about condom effectiveness—while helpful, condoms provide incomplete protection against HSV-2 transmission. 1
• Do not delay counseling about transmission risk until after the first recurrence—comprehensive education should occur at initial diagnosis. 2, 8

Special Consideration: Pregnancy

• Women of childbearing age must be counseled about neonatal transmission risk and instructed to inform obstetric providers of their HSV-2 status. 1
• Suppressive therapy starting at 36 weeks gestation should be considered to reduce viral shedding at delivery. 2